Yhojan Rodríguez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yhojan Rodríguez has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Juan-Manuel Anaya
Universidad de la Costa, Barranquilla, Colombia
9 shared publications - Carolina Ramírez-Santana
Center for Autoimmune Diseases Research (CREA), School of Medicine and Health Sciences, Universidad del Rosario, Bogota, Colombia
7 shared publications - Diana M. Monsalve
Center for Autoimmune Diseases Research (CREA), School of Medicine and Health Sciences, Universidad del Rosario, Bogota, Colombia
6 shared publications - Yeny Acosta-Ampudia
Center for Autoimmune Diseases Research (CREA), School of Medicine and Health Sciences, Universidad del Rosario, Bogota, Colombia
6 shared publications - Manuel Rojas
Center for Autoimmune Diseases Research (CREA), School of Medicine and Health Sciences, Universidad del Rosario, Bogota, Colombia
5 shared publications - Nicolás Molano-González
Clinical Research Group, School of Medicine and Health Sciences, Universidad del Rosario, Bogotá, Colombia
3 shared publications
Latest Publications
- Open Access
- 8 August 2023
- Published by Frontiers Media SA in Frontiers in Molecular Biosciences
- Vol. 10, 1215039
Metabolic fingerprinting of systemic sclerosis: a systematic review
Introduction: Systemic sclerosis (SSc) is a chronic autoimmune disease, marked by an unpredictable course, high morbidity, and increased mortality risk that occurs especially in the diffuse and rapidly progressive forms of the disease, characterized by fibrosis of the skin and internal organs and endothelial dysfunction. Recent studies suggest that the identification of altered metabolic pathways may play a key role in understanding the pathophysiology of the disease. Therefore, metabolomics might be pivotal in a better understanding of these pathogenic mechanisms.Methods: Through a systematic review of the literature following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Guidelines (PRISMA), searches were done in the PubMed, EMBASE, Web of Science, and Scopus databases from 2000 to September 2022. Three researchers independently reviewed the literature and extracted the data based on predefined inclusion and exclusion criteria.Results: Of the screened studies, 26 fulfilled the inclusion criteria. A total of 151 metabolites were differentially distributed between SSc patients and healthy controls (HC). The main deregulated metabolites were those derived from amino acids, specifically homocysteine (Hcy), proline, alpha-N-phenylacetyl-L-glutamine, glutamine, asymmetric dimethylarginine (ADMA), citrulline and ornithine, kynurenine (Kyn), and tryptophan (Trp), as well as acylcarnitines associated with long-chain fatty acids and tricarboxylic acids such as citrate and succinate. Additionally, differences in metabolic profiling between SSc subtypes were identified. The diffuse cutaneous systemic sclerosis (dcSSc) subtype showed upregulated amino acid-related pathways involved in fibrosis, endothelial dysfunction, and gut dysbiosis. Lastly, potential biomarkers were evaluated for the diagnosis of SSc, the identification of the dcSSc subtype, pulmonary arterial hypertension, and interstitial lung disease. These potential biomarkers are within amino acids, nucleotides, carboxylic acids, and carbohydrate metabolism.Discussion: The altered metabolite mechanisms identified in this study mostly point to perturbations in amino acid-related pathways, fatty acid beta-oxidation, and in the tricarboxylic acid cycle, possibly associated with inflammation, vascular damage, fibrosis, and gut dysbiosis. Further studies in targeted metabolomics are required to evaluate potential biomarkers for diagnosis, prognosis, and treatment response.
- 8 August 2023
- Published by Frontiers Media SA in Frontiers in Molecular Biosciences
- Vol. 10, 1215039
Open AccessMetabolic fingerprinting of systemic sclerosis: a systematic review
Introduction: Systemic sclerosis (SSc) is a chronic autoimmune disease, marked by an unpredictable course, high morbidity, and increased mortality risk that occurs especially in the diffuse and rapidly progressive forms of the disease, characterized by fibrosis of the skin and internal organs and endothelial dysfunction. Recent studies suggest that the identification of altered metabolic pathways may play a key role in understanding the pathophysiology of the disease. Therefore, metabolomics might be pivotal in a better understanding of these pathogenic mechanisms.Methods: Through a systematic review of the literature following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Guidelines (PRISMA), searches were done in the PubMed, EMBASE, Web of Science, and Scopus databases from 2000 to September 2022. Three researchers independently reviewed the literature and extracted the data based on predefined inclusion and exclusion criteria.Results: Of the screened studies, 26 fulfilled the inclusion criteria. A total of 151 metabolites were differentially distributed between SSc patients and healthy controls (HC). The main deregulated metabolites were those derived from amino acids, specifically homocysteine (Hcy), proline, alpha-N-phenylacetyl-L-glutamine, glutamine, asymmetric dimethylarginine (ADMA), citrulline and ornithine, kynurenine (Kyn), and tryptophan (Trp), as well as acylcarnitines associated with long-chain fatty acids and tricarboxylic acids such as citrate and succinate. Additionally, differences in metabolic profiling between SSc subtypes were identified. The diffuse cutaneous systemic sclerosis (dcSSc) subtype showed upregulated amino acid-related pathways involved in fibrosis, endothelial dysfunction, and gut dysbiosis. Lastly, potential biomarkers were evaluated for the diagnosis of SSc, the identification of the dcSSc subtype, pulmonary arterial hypertension, and interstitial lung disease. These potential biomarkers are within amino acids, nucleotides, carboxylic acids, and carbohydrate metabolism.Discussion: The altered metabolite mechanisms identified in this study mostly point to perturbations in amino acid-related pathways, fatty acid beta-oxidation, and in the tricarboxylic acid cycle, possibly associated with inflammation, vascular damage, fibrosis, and gut dysbiosis. Further studies in targeted metabolomics are required to evaluate potential biomarkers for diagnosis, prognosis, and treatment response.
- Open Access
- 1 August 2020
- Published by Wiley in Clinical Endocrinology
- Vol. 93 (4) , 375-389
Prevalence of latent and overt polyautoimmunity in autoimmune thyroid disease: A systematic review and meta‐analysis
Background: Thyroid autoimmunity is the most frequent condition involved in polyautoimmunity (PolyA). However, the frequency of latent and overt PolyA in patients with autoimmune thyroid disease (AITD) as the index condition is unknown. Therefore, the purpose of this study was to determine the prevalence of these types of PolyA in patients with AITD as the index condition.Methods: This study adhered to the relevant sections of the Preferred Reporting Items for Systematic Reviews and Meta‐analyses (PRISMA) guideline. Searches through MEDLINE, Embase and LILACS were done to find articles in Spanish and English. Relevant vocabulary terms and key terms related to AITD and other autoimmune diseases were used. Two investigators independently screened the eligible studies, extracted data and assessed the quality and risk of bias. Fixed and random effect models were used accordingly. Cluster analysis was used to determine similarities among diseases in the articles included (based on Jaccard index).Results: A total of 56 articles fulfilled the inclusion criteria. Of these, 25 were case‐controls, 17 were cohorts, and 14 were cross‐sectional studies. These studies included a total of 47 509 patients. Female was the predominant gender and included 38 950 patients (81.23%, 95% CI: 80.85‐81.60). Graves’ disease (GD) was the most common type of thyroid autoimmunity (69.16%, 95% CI: 68.23‐70.07). Globally, overt PolyA was found in 13.46% of the patients with AITD. This type of PolyA was represented mainly by type 1 diabetes and autoimmune gastritis. Latent PolyA was presented in 17.45% of the patients, and anti‐proinsulin, anti‐parietal cells and dsDNA antibodies were the most common. HT had the highest frequency of overt PolyA in Europe (15.60%, 95% CI: 14.72‐16.53), whereas latent PolyA was most common in patients with GD in Asia (21.03%, 95% CI: 17.76‐24.71). Overt and latent PolyA were associated with gastrointestinal and endocrinological ADs in most of cases and clustered with rheumatological, dermatological and neurological ADs.Conclusions: Latent and overt PolyA are common in patients with AITD. These results provide insightful information for early diagnosis and management of concurrent ADs in patients with AITD. Aggregation of ADs in different clusters may help to define different phenotypes associated with thyroid autoimmunity that are critically relevant in clinical settings.
- 1 August 2020
- Published by Wiley in Clinical Endocrinology
- Vol. 93 (4) , 375-389
Open AccessPrevalence of latent and overt polyautoimmunity in autoimmune thyroid disease: A systematic review and meta‐analysis
Background: Thyroid autoimmunity is the most frequent condition involved in polyautoimmunity (PolyA). However, the frequency of latent and overt PolyA in patients with autoimmune thyroid disease (AITD) as the index condition is unknown. Therefore, the purpose of this study was to determine the prevalence of these types of PolyA in patients with AITD as the index condition.Methods: This study adhered to the relevant sections of the Preferred Reporting Items for Systematic Reviews and Meta‐analyses (PRISMA) guideline. Searches through MEDLINE, Embase and LILACS were done to find articles in Spanish and English. Relevant vocabulary terms and key terms related to AITD and other autoimmune diseases were used. Two investigators independently screened the eligible studies, extracted data and assessed the quality and risk of bias. Fixed and random effect models were used accordingly. Cluster analysis was used to determine similarities among diseases in the articles included (based on Jaccard index).Results: A total of 56 articles fulfilled the inclusion criteria. Of these, 25 were case‐controls, 17 were cohorts, and 14 were cross‐sectional studies. These studies included a total of 47 509 patients. Female was the predominant gender and included 38 950 patients (81.23%, 95% CI: 80.85‐81.60). Graves’ disease (GD) was the most common type of thyroid autoimmunity (69.16%, 95% CI: 68.23‐70.07). Globally, overt PolyA was found in 13.46% of the patients with AITD. This type of PolyA was represented mainly by type 1 diabetes and autoimmune gastritis. Latent PolyA was presented in 17.45% of the patients, and anti‐proinsulin, anti‐parietal cells and dsDNA antibodies were the most common. HT had the highest frequency of overt PolyA in Europe (15.60%, 95% CI: 14.72‐16.53), whereas latent PolyA was most common in patients with GD in Asia (21.03%, 95% CI: 17.76‐24.71). Overt and latent PolyA were associated with gastrointestinal and endocrinological ADs in most of cases and clustered with rheumatological, dermatological and neurological ADs.Conclusions: Latent and overt PolyA are common in patients with AITD. These results provide insightful information for early diagnosis and management of concurrent ADs in patients with AITD. Aggregation of ADs in different clusters may help to define different phenotypes associated with thyroid autoimmunity that are critically relevant in clinical settings.
- Open Access
- 1 December 2018
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 395, 47-53
Concurrent Guillain-Barré syndrome, transverse myelitis and encephalitis post-Zika: A case report and review of the pathogenic role of multiple arboviral immunity
- 1 December 2018
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 395, 47-53
Open AccessConcurrent Guillain-Barré syndrome, transverse myelitis and encephalitis post-Zika: A case report and review of the pathogenic role of multiple arboviral immunity
- Open Access
- 9 November 2018
- Published by Wiley in Clinical Case Reports
- Vol. 7 (1) , 19-23
Impact of hyperprolactinemia in a patient with polyautoimmunity
Hyperprolactinemia has been proposed as a triggering factor for autoimmune diseases. The increased levels of prolactin could induce an abnormal immune response. Herein, we present a patient with hyperprolactinemia who developed polyautoimmunity. Patient's symptoms were associated with slightly raised levels of prolactin (20‐40 ng/mL) and administration of dopaminergic agonists.
- 9 November 2018
- Published by Wiley in Clinical Case Reports
- Vol. 7 (1) , 19-23
Open AccessImpact of hyperprolactinemia in a patient with polyautoimmunity
Hyperprolactinemia has been proposed as a triggering factor for autoimmune diseases. The increased levels of prolactin could induce an abnormal immune response. Herein, we present a patient with hyperprolactinemia who developed polyautoimmunity. Patient's symptoms were associated with slightly raised levels of prolactin (20‐40 ng/mL) and administration of dopaminergic agonists.
- Open Access
- 13 July 2018
- Published by Wiley in Annals of Clinical and Translational Neurology
- Vol. 5 (9) , 1139
Comment on: Zika virus and Guillain–Barré syndrome in Bangladesh
- 13 July 2018
- Published by Wiley in Annals of Clinical and Translational Neurology
- Vol. 5 (9) , 1139
Open AccessComment on: Zika virus and Guillain–Barré syndrome in Bangladesh
- 1 March 2018
- Published by Elsevier in Journal of Autoimmunity
- Vol. 88, 21-42
Tick-borne diseases and autoimmunity: A comprehensive review
- 1 March 2018
- Published by Elsevier in Journal of Autoimmunity
- Vol. 88, 21-42
Tick-borne diseases and autoimmunity: A comprehensive review
- 12 February 2018
- Published by Taylor & Francis in Expert Review of Precision Medicine and Drug Development
- Vol. 3 (2) , 119-135
Progress towards precision medicine for lupus: the role of genetic biomarkers
Systemic lupus erythematosus (SLE) is the prototypical systemic autoimmune disease (AD). Precision medicine gives clinicians and society access to the information needed to create individually tailored programs to predict, prevent, and treat SLE. Although several biomarkers have been described for SLE, current expansion of knowledge on lupus genetics makes the implementation of genetic biomarkers possible. Herein, a comprehensive description of relevant SLE genetic biomarkers from the precision medicine perspective is offered. National inception cohorts should be created and the implementation of translational programs for the control of ADs such as SLE should be put into practice. Factors that are predictive of developing these conditions should be examined at the population level in order to establish preventive measures in at-risk individuals for whom healthcare should be personalized/precise and participatory. The implementation of such a program will allow the discovery of new mechanisms and a new taxonomy of ADs. The translational model should also involve educational and training programs together with digital participatory surveillance systems. Healthcare’s one-size-fits-all approach to treating patients will be replaced with a personalized/precision approach to medicine that focuses on individuals and each family member.
- 12 February 2018
- Published by Taylor & Francis in Expert Review of Precision Medicine and Drug Development
- Vol. 3 (2) , 119-135
Progress towards precision medicine for lupus: the role of genetic biomarkers
Systemic lupus erythematosus (SLE) is the prototypical systemic autoimmune disease (AD). Precision medicine gives clinicians and society access to the information needed to create individually tailored programs to predict, prevent, and treat SLE. Although several biomarkers have been described for SLE, current expansion of knowledge on lupus genetics makes the implementation of genetic biomarkers possible. Herein, a comprehensive description of relevant SLE genetic biomarkers from the precision medicine perspective is offered. National inception cohorts should be created and the implementation of translational programs for the control of ADs such as SLE should be put into practice. Factors that are predictive of developing these conditions should be examined at the population level in order to establish preventive measures in at-risk individuals for whom healthcare should be personalized/precise and participatory. The implementation of such a program will allow the discovery of new mechanisms and a new taxonomy of ADs. The translational model should also involve educational and training programs together with digital participatory surveillance systems. Healthcare’s one-size-fits-all approach to treating patients will be replaced with a personalized/precision approach to medicine that focuses on individuals and each family member.
- 1 December 2017
- Published by Elsevier in Autoimmunity Reviews
- Vol. 16 (12) , 1237-1245
Zika virus and autoimmunity. One-step forward
- 1 December 2017
- Published by Elsevier in Autoimmunity Reviews
- Vol. 16 (12) , 1237-1245
Zika virus and autoimmunity. One-step forward
- Open Access
- 25 November 2017
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 15 (1) , 239
Cytokine and autoantibody clusters interaction in systemic lupus erythematosus
Evidence supports the existence of different subphenotypes in systemic lupus erythematosus (SLE) and the pivotal role of cytokines and autoantibodies, which interact in a highly complex network. Thus, understanding how these complex nonlinear processes are connected and observed in real-life settings is a major challenge. Cluster approaches may assist in the identification of these subphenotypes, which represent such a phenomenon, and may contribute to the development of personalized medicine. Therefore, the relationship between autoantibody and cytokine clusters in SLE was analyzed. This was an exploratory study in which 67 consecutive women with established SLE were assessed. Clinical characteristics including disease activity, a 14-autoantibody profile, and a panel of 15 serum cytokines were measured simultaneously. Mixed-cluster methodology and bivariate analyses were used to define autoantibody and cytokine clusters and to identify associations between them and related variables. First, three clusters of autoantibodies were defined: (1) neutral, (2) antiphospholipid antibodies (APLA)-dominant, and (3) anti-dsDNA/ENA-dominant. Second, eight cytokines showed levels above the threshold thus making possible to find 4 clusters: (1) neutral, (2) chemotactic, (3) G-CSF dominant, and (4) IFNα/Pro-inflammatory. Furthermore, the disease activity was associated with cytokine clusters, which, in turn, were associated with autoantibody clusters. Finally, when all biomarkers were included, three clusters were found: (1) neutral, (2) chemotactic/APLA, and (3) IFN/dsDNA, which were also associated with disease activity. These results support the existence of three SLE cytokine-autoantibody driven subphenotypes. They encourage the practice of personalized medicine, and support proof-of-concept studies.
- 25 November 2017
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 15 (1) , 239
Open AccessCytokine and autoantibody clusters interaction in systemic lupus erythematosus
Evidence supports the existence of different subphenotypes in systemic lupus erythematosus (SLE) and the pivotal role of cytokines and autoantibodies, which interact in a highly complex network. Thus, understanding how these complex nonlinear processes are connected and observed in real-life settings is a major challenge. Cluster approaches may assist in the identification of these subphenotypes, which represent such a phenomenon, and may contribute to the development of personalized medicine. Therefore, the relationship between autoantibody and cytokine clusters in SLE was analyzed. This was an exploratory study in which 67 consecutive women with established SLE were assessed. Clinical characteristics including disease activity, a 14-autoantibody profile, and a panel of 15 serum cytokines were measured simultaneously. Mixed-cluster methodology and bivariate analyses were used to define autoantibody and cytokine clusters and to identify associations between them and related variables. First, three clusters of autoantibodies were defined: (1) neutral, (2) antiphospholipid antibodies (APLA)-dominant, and (3) anti-dsDNA/ENA-dominant. Second, eight cytokines showed levels above the threshold thus making possible to find 4 clusters: (1) neutral, (2) chemotactic, (3) G-CSF dominant, and (4) IFNα/Pro-inflammatory. Furthermore, the disease activity was associated with cytokine clusters, which, in turn, were associated with autoantibody clusters. Finally, when all biomarkers were included, three clusters were found: (1) neutral, (2) chemotactic/APLA, and (3) IFN/dsDNA, which were also associated with disease activity. These results support the existence of three SLE cytokine-autoantibody driven subphenotypes. They encourage the practice of personalized medicine, and support proof-of-concept studies.
- 1 April 2017
- Published by Elsevier in Autoimmunity Reviews
- Vol. 16 (4) , 327-334
Autoimmunity in Guillain-Barré syndrome associated with Zika virus infection and beyond
- 1 April 2017
- Published by Elsevier in Autoimmunity Reviews
- Vol. 16 (4) , 327-334
Autoimmunity in Guillain-Barré syndrome associated with Zika virus infection and beyond